Search clinical trials for: TPN171H 40 mg Group
Total 0 results
Nothing found
Sponsors and Collaborators
- IRCCS Istituto Auxologico Italiano, Milano, Italy
- National Institute of Cardiovascular Diseases, Bangladesh
- Direction Interarmées du Service de Santé des Armées (DIASS) de Cayenne, French Guiana
- AlpinARC
- Glasgow Western Infirmary
- Hospitales Universitarios Virgen del Rocío
- The Australia-Israel Scientific Exchange Foundation (AISEF)
- ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO
- Dr Philippe METELLUS
- Sublimity Therapeutics Holdco Limited
- ADOR - Territorial Support Network, Device and Tools for Primary Care Teams
- Sahachat Aueyingsak
- Ouctomes Research Consortium, Cleveland Clinic, Ohio, USA
- ECMC
- Daniela Pacella - University of Naples Federico II, Naples
- Bassam Abdulkarim
- the people hospital of Linzhi
- Centro Universitário Franciscano
- Åke Wibergs Stiftelse
- Etan Orgel
- View Full List
Medical Conditions
- Progression to PD-1 Antibody
- Eosinophil Blood Count
- Adult Patients Undergoing Surgery That Requires General Anesthesia
- Interviews
- Patients With Leptomeningeal Disease
- Hyperprolinemia
- Value-Based Health Insurance
- Ability to Swim 100m Independent Freestyle
- Pancreaticoduodenectomy
- Genetic Risk Factor
- Very Long Chain Acyl Coa Dehydrogenase Deficiency
- Panniculectomy
- Legal History
- Initiation of Depo-Provera (DMPA)
- Bladder Cancer TNM Staging Primary Tumor (T) T2B
- Implanted With Any Currently (and Any Future) FDA-approved Medtronic ICD or CRT Device
- Orthopaedic Disorders
- Degenerative Spondylolisthesis G1
- Transitional Cell Carcinoma of Renal Pelvis
- Failed Open Reduction Internal Fixation (ORIF) of a Radial Head Fracture
- View Full List
Drug Interventions
- Metoclopramide + dexamethasone
- 6% hetastarch
- Injectable Insulin
- Cefuroxime 750mg oral
- Paliperidone palmitate
- Gefitinib
- Erythropoietin
- Prasugrel
- Antibiotic treatment
- Omeprazole 20mg
- 0% N2O
- 5-Fluoro-uracil
- Mepivacaine
- Epirubicin hydrochloride
- UFUR and Iressa
- HBM4003 and Triprilimab
- Nimotuzumab
- IV rtPA (intravenous recombinant plasminogen activator)
- ASP8062
- ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
- View Full List
CROs by country
- Contract Research Organizations in Albania
- Contract Research Organizations in Austria
- Contract Research Organizations in Ecuador
- Contract Research Organizations in Gambia
- Contract Research Organizations in Iran
- Contract Research Organizations in Kazakhstan
- Contract Research Organizations in Kosovo
- Contract Research Organizations in Madagascar
- Contract Research Organizations in Mali
- Contract Research Organizations in New Zealand
- Contract Research Organizations in Slovakia
- Contract Research Organizations in Turkmenistan
- Contract Research Organizations in Vietnam
- CRO list by country